Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide

Clinical Drug Investigation

Volumn 34, Issue 6, 2014, Pages 403-411

  Bramlage, Peter ^a   Ketelhut, Reinhard ^b   Fronk, Eva Maria ^c   Wolf, Wolf Peter ^c   Smolnik, Rüdiger ^c   Zemmrich, Claudia ^a   Schmieder, Roland E ^d  

^a Institut für Pharmakologie und Präventive Medizin   (Germany)

^b Universitatsklinikum Hindenburgdamm   (Germany)

^c DAIICHI SANKYO CO   (Japan)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; HYDROCHLOROTHIAZIDE; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT TOOL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORISKY MEDICATION ADHERENCE SCALE 8; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SELF EVALUATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; EUROPE; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; EUROPE; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; TETRAZOLES; YOUNG ADULT;

EID: 84901651570     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0188-z     Document Type: Article

References (35)

1. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-9. (Pubitemid 38293521)
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force M. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357
3. Cowart JB, Taylor AA. Should two-drug initial therapy for hypertension be recommended for all patients? Curr Hypertens Rep. 2012;14:324-32.
4. Fifth Joint Task Force of the European Society of C, European Association of E, European Association of Percutaneous Cardiovascular I, European Heart Rhythm A, Heart Failure A, European Association for Cardiovascular P, Rehabilitation, European Atherosclerosis S, International Society of Behavioural M, European Stroke O, European Society of H, European Association for the Study of D, European Society of General Practice/Family M, International Diabetes Federation E, European Heart N. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19:585-667.
5. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008;4:653-64. (Pubitemid 352037923)
6. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlof B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Avoiding cardiovascular events through CtiPLwSHI: predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the Accomplish Study. Blood Press. 2008;17:7-17. (Pubitemid 351890487)
7. Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens. 2009;11:324-32.
8. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril hcl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324-32.
9. Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens. 2009;11:475-82.
10. Izzo JL Jr, Chrysant SG, Kereiakes DJ, Littlejohn Iii T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the Trinity Ambulatory Blood Pressure Substudy. J Clin Hypertens. 2011;13:873-80.
11. Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens. 2012;14:149-57.
12. Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the coach trial. J Hum Hypertens. 2010;24:831-8.
13. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the trinity multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252-69.
14. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348-54.
15. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manage Care. 2009;15:59-66.
16. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with anti-hypertensive monotherapy in 13 managed care organizations. J Manage Care Pharm. 2006;12:239-45. (Pubitemid 47400613)
17. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-71. (Pubitemid 44903860)
18. Hill MN, Miller NH, DeGeest S, American Society of Hypertension Writing Group. Ash position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens. 2010;12:757-64.
19. Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE, Frohlich ED, Re RN. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58:804-10.
20. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610-8.
21. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-605.
22. Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013;7:27-39.
23. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Berard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207-18.
24. Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, Berard A. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69:74-84.
25. Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L, Lalonde L, Moreau P, Perreault S. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke J Cereb Circ. 2009;40:213-20.
26. Prado JC Jr, Kupek E, Mion D Jr. Validity of four indirect methods to measure adherence in primary care hypertensives. J Hum Hypertens. 2007;21:579-84. (Pubitemid 47018633)
27. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol. 2009;8:18.
28. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1-94.
29. Esposti LD, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S, Esposti ED. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens. 2004;6:76-84.
30. Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:1055-61. (Pubitemid 47561800)
31. Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens. 2007;9:692-700.
32. Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a pharmo study. Pharmacoepidemiol Drug Saf. 2005;14:795-803. (Pubitemid 41684472)
33. Veronesi M, Cicero AF, Prandin MG, Dormi A, Cosentino E, Strocchi E, Borghi C. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3:999-1005.
34. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-81. (Pubitemid 28421488)
35. Tocci G, Paneni F, Passerini J, Volpe M. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine- hydrochlorothiazide therapy. Expert Opin Pharmacother. 2012;13:2687-97.